# Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

> **NCT04249076** · PHASE3 · COMPLETED · sponsor: **Salvat** · enrollment: 215 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** Clobetasol Propionate
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT04249076
- **Lead sponsor:** Salvat
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-04
- **Primary completion:** 2021-04-14
- **Final completion:** 2021-04-14
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04249076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04249076, "Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04249076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*